Monitoring and treating colorectal cancer based on tumor DNA
Part of Cancer, Digestive system clinical trials.
This study looks at using a blood test to find cancer DNA and guide treatment for people with stage IV colorectal cancer that has a specific genetic pattern. The goal is to see if this approach can help monitor the cancer and personalize treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have stage IV colorectal cancer that is 'mismatch repair deficient' or 'MSI-H'.
- You have not had immunotherapy for your current cancer.
- You are well enough to be up and about (ECOG 0-1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is studying a blood test that looks for tiny bits of cancer DNA after surgery for stage III colorectal cancer. The goal is to find out how well this test can predict whether cancer might come back, so you and your doctor can make better treatment decisions.
This trial tests a new immunotherapy drug (AK104) given before and after surgery for a specific type of colon cancer that is MSI-H or dMMR. The goal is to see if the drug helps shrink the tumor and prevent the cancer from coming back.
This trial tests whether using a simple blood test (ctDNA) can help guide treatment with immunotherapy drugs (PD-1 inhibitors) for people with a specific type of colon cancer (MSI-high/dMMR). The goal is to see if this approach can improve outcomes and reduce side effects compared to standard care.
This trial tests a personalized immune therapy (like a custom vaccine) for people with colorectal cancer that has a positive ctDNA MRD test after surgery. It aims to use the body's own immune system to target any remaining cancer cells and prevent the cancer from coming back.
This study looks at whether a blood test for tumor DNA (ctDNA) can predict how well immunotherapy works in people with advanced or locally advanced colorectal cancer that has specific genetic features (dMMR/MSI-H). If you qualify, the trial will monitor your ctDNA levels while you receive standard immunotherapy to see if changes in those levels can show early on if the treatment is working.
This study is testing whether a blood test that looks for tiny bits of tumor DNA (ctDNA methylation) can help monitor how well treatment is working in people with colorectal cancer that has spread. If you are getting radiation and chemotherapy (with or without an immunotherapy drug), this trial may help your doctor see if the treatment is working sooner.
Hear when a new Colorectal Cancer (MSI-H) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.